News

FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight
DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only ...
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results ...
Pharm Exec2mon
FDA Approves Novartis’ Fabhalta for C3 Glomerulopathy
The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...
MedCity News2mon
Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels
The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in-a-product potential. But competition looms from a rival drug taking a similar approach.
Benzinga.com2mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
The FDA approved Novartis' Fabhalta, making it the first and only treatment for adults with C3 glomerulopathy. Fabhalta showed sustained proteinuria reduction in Phase 3 trials, with effects seen ...
FiercePharma2mon
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatment endorsed by the agency for the ultrarare kidney disease ...
WGHP2mon
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...
manilatimes2mon
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 - Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...
The American Journal of Managed Care2mon
FDA Approves Oral Iptacopan for C3 Glomerulopathy
Iptacopan's (Fabhalta; Novartis) approval makes it the first and only treatment approved for C3 glomerulopathy. The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults ...